Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Wednesday 29 April, 2020

JP Morgan Sec LLC

Allergan plc 38.5(b)

RNS Number : 3293L
J.P. Morgan Securities LLC
29 April 2020
 

Ap27

 

 

FORM   38.5(b)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED 
INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

 

1.  KEY   INFORMATION

 

Nameofexemptprincipaltrader

J.P Morgan Securities LLC

Companydealtin

Allergan plc

Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate (Note 1)

Ordinary Share

Date of dealing

28 April 2020

 

2.  INTERESTS AND SHORT POSITIONS

 

(a)  Interests   and   short   positions   (following   dealing)   in   the   class   of   relevant   security   dealt   in   (Note   2)

 

 

Long

Short

 

Number

 

(%)

Number

 

(%)

 5,339,453  1.62

 3,983,328  1.21

(2) Derivatives (other than options)

 3,817,157  1.16

 4,583,355  1.39

(3)Optionsandagreementstopurchase/sell

 305,000  0.09

 0  0.00

Total

 9,461,610  2.87

 8,566,683  2.60

             

 

 

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in  (Note   2)

 

Classofrelevantsecurity:

Long

Short

 

Number

 

(%)

Number

 

(%)

 

 

(2) Derivatives (other than options)

 

 

(3)Optionsandagreementstopurchase/sell

 

 

Total

 

 

             

 

Ap28

 

 

3.  DEALINGS  (Note   3)

 

(a)  Purchases and sales

 

Purchase/sale

Numberofrelevantsecurities

Priceperunit (Note 4)

Purchases

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales

100

200

100

62

100

100

20

518

300

1,418

528

300

3

657

2

400

100

100

100

2

1

50

200

1

100

500

9

500

529

115

 

40

400

77

3,321

29

9

186.8000 USD

186.8550 USD

186.8600 USD

186.8900 USD

186.9100 USD

187.0300 USD

187.0700 USD

187.1108 USD

187.1367 USD

187.3500 USD

187.4223 USD

187.4700 USD

187.4933 USD

187.5076 USD

187.5750 USD

187.5875 USD

187.6200 USD

187.6302 USD

187.6400 USD

187.6450 USD

187.6800 USD

187.6836 USD

187.7050 USD

187.7200 USD

187.7600 USD

187.7820 USD

187.8200 USD

188.0740 USD

188.0968 USD

189.0006 USD

 

187.0700 USD

187.2025 USD

187.2077 USD

187.3500 USD

187.7300 USD

187.8200 USD

 

 

(b)  Derivatives transactions (other than options transactions)

 

Productname,

e.g. CFD

Natureoftransaction

(Note 5)

Numberofrelevantsecurities

(Note 6)

Priceperunit

(Note 4)

Equity Swaps

Long

20

187.0700 USD

 

 

(c)  Options transactions in respect of existing relevant securities

 

 

(i)  Writing,   selling, purchasing or varying

 

Productname,

e.g. call option

Writing, selling,purchasing,varyingetc.

Numberofsecurities towhichtheoptionrelates (Note 7)

Exercise price

Type, e.g.American,Europeanetc.

Expiry date

Optionmoney paid/receivedperunit (Note 4)

 

 

 

 

 

 

 

 

 

(ii)  Exercising

 

Productname,

e.g. call option

Numberofsecurities

Exercisepriceper unit (Note 4)

 

 

 

 

 

(d)  Other   dealings   (including   transactions   in   respect   of   new   securities)   (Note   3)

 

Nature of transaction

(Note 7)

Details

Price per unit

(if applicable) (Note 4)

 

 

 

 

Ap29

 

4.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities 

under   any   option   referred   to   on   this   form   or   relating   to   the   voting   rights  or future acquisition 

or disposal of any relevant securities to which any derivative referred to on this form is referenced. 

If   none,   this   should   be   stated.

 

 

 

 

 

 

 

 

Is a Supplemental Form 38.5(b) attached?  (Note   8)    YES

 

 

Dateofdisclosure

29 April 2020

Contactname

Alwyn Basch

Telephone number

020 7742 7407

Name of offeree/offeror with which connected

Allergan plc

Nature of connection (Note 9)

Financial Advisor to Allergan plc

 

 

 

 

Ap31

 

 

SUPPLEMENTAL   FORM   38.5(b)

 

 

 

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DETAILS   OF OPEN POSITIONS

 

(This   form   should   be   attached   to   Form   38.5(b))   OPEN POSITIONS  (Note   1)

 

Productname,

e.g. call option

Written orpurchased

Numberofrelevant securitiestowhichtheoptionorderivativerelates

Exercise price (Note 2)

Type, e.g.American,Europeanetc.

Expiry date

Put Option

Put Option

Written

Written

300,000

5,000

150.00

140.00

American

American

19JUN20

19JUN20

 

 

 

 

Notes

 

1.  Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

 

2.  For all prices and other monetary amounts, the currency must be stated.

 

For full details of disclosure requirements, see Rules 8 and

38.5 of the Rules. If in doubt, consult the Panel.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEZZGZDGLVGGZM

a d v e r t i s e m e n t